US 11,813,159 B2
Intraocular drug delivery platform
Glenn Robert Sussman, Aliso Viejo, CA (US); Craig Alan Cable, II, Aliso Viejo, CA (US); and Malik Y. Kahook, Aliso Viejo, CA (US)
Assigned to SpyGlass Pharma, Inc., Aliso Viejo, CA (US); and The Regents of the University of Colorado, a body corporate, Denver, CO (US)
Filed by SpyGlass Pharma, Inc., Aliso Viejo, CA (US); and The Regents of the University of Colorado, a body corporate, Denver, CO (US)
Filed on Feb. 24, 2021, as Appl. No. 17/183,985.
Claims priority of provisional application 62/980,620, filed on Feb. 24, 2020.
Prior Publication US 2021/0267751 A1, Sep. 2, 2021
Int. Cl. A61F 2/16 (2006.01)
CPC A61F 2/16 (2013.01) [A61F 2002/169 (2015.04); A61F 2002/16901 (2015.04); A61F 2002/16902 (2015.04); A61F 2220/0025 (2013.01); A61F 2250/0068 (2013.01)] 10 Claims
OG exemplary drawing
 
1. An intraocular drug delivery platform for use with an intraocular lens (IOL), comprising:
a flat ring comprising an anterior surface, a posterior surface opposite the anterior surface, and a central aperture formed by the ring,
a first haptic coupled to and extending outwards from the ring,
a second haptic coupled to and extending outwards from the ring,
a first drug eluting mass comprising a therapeutic agent coupled to the anterior surface of the ring,
a second drug eluting mass comprising the therapeutic agent coupled to the anterior surface of the ring and positioned directly opposite of the first drug eluting mass,
a skirt extending posteriorly from the posterior surface of the ring and partially or fully circumscribing the central aperture, and
an intraocular lens (IOL) configured to be retained in a position by the intraocular drug delivery platform, the OIL comprising a first lens haptic and a second lens haptic,
wherein the skirt comprises an inner diameter sized and configured to retain the OIL within the skirt.